AbbVie (ABBV) raises dividend 5.5% to $1.73, keeping a 13-year streak alive
As seen on the 24/7 Wall St. homepage on July 15, 2026.
AbbVie hiked its dividend 5.5% to $1.73 per share, extending a 13-year streak of unbroken payouts even as biosimilar pressure weighs on Humira's top-line growth.
Continue ReadingShow less
AbbVie's latest dividend hike brings the quarterly payout to $1.73 per share, up 5.5% from a year ago, with an ex-dividend date of July 15, 2026. On a trailing annual basis, shareholders are now collecting $6.83 per share, and at current prices the stock yields 2.8%. The increase marks the thirteenth consecutive year the company has raised or maintained its dividend without interruption.
The backdrop for the hike is not without complication. Biosimilar competition has been eroding Humira's revenue as cheaper alternatives enter the market, putting pressure on one of the company's historically dominant revenue drivers. Despite that headwind, AbbVie has chosen to push the payout higher rather than hold it steady, a signal that management views its broader drug portfolio as capable of sustaining the commitment.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
For dividend-focused investors, the combination of a 2.8% yield, a 13-year payout streak, and a 5.5% annual growth rate makes ABBV a name worth tracking closely as the Humira transition continues to play out.
Sources
Mentioned: ABBV